Background
Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects.• Intercellular adhesion molecule-1 (ICAM-1): From molecular functions to clinical applications in cancer investigation., PMID:39317271• Quercetin inhibits TNF-α induced HUVECs apoptosis and inflammation via downregulating NF-kB and AP-1 signaling pathway in vitro., PMID:32957369• ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer., PMID:34381029• The Roles of Lipoprotein in Psoriasis., PMID:32013194• Islet beta-cells and intercellular adhesion molecule-1 (ICAM-1): Integrating immune responses that influence autoimmunity and graft rejection., PMID:37619906• Genetic Variation in Intercellular Adhesion Molecule-1 (ICAM-1) and Diastolic Heart Failure in the Black Population in the United States., PMID:37062471• Systematic pan-cancer analysis insights into ICAM1 as an immunological and prognostic biomarker., PMID:38979944•Fusobacterium nucleatumpromotes colorectal cancer cells adhesion to endothelial cells and facilitates extravasation and metastasis by inducing ALPK1/NF-κB/ICAM1 axis., PMID:35220887• Gene regulation of intracellular adhesion molecule-1 (ICAM-1): A molecule with multiple functions., PMID:34715236• Intercellular adhesion molecule-1 suppresses TMZ chemosensitivity in acquired TMZ-resistant gliomas by increasing assembly of ABCB1 on the membrane., PMID:38924997